You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR LIPIODOL


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for LIPIODOL

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT03268499 ↗ TACE Emulsion Versus Suspension Recruiting Chinese University of Hong Kong Phase 2 2016-09-01 The aim of the study was to evaluate the safety and efficacy of using the new formulation (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the conventional formulation (Lipiodol-cisplatin emulsion). This is a prospective, parallel-group, open-label randomized, phase II study that is conducted in accordance to the Declaration of Helsinki and international standards of Good Clinical Practice, and approved by the institutional review board. Eligible patients were randomized into either a treatment arm of Lipiodol-cisplatin suspension or a control arm of Lipiodol-cisplatin emulsion with a 1:1 ratio.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for LIPIODOL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00116454 ↗ Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed ANRS, Emerging Infectious Diseases Phase 3 2005-07-01 The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation.
NCT00116454 ↗ Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Phase 3 2005-07-01 The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation.
NCT00470340 ↗ Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients Terminated Assistance Publique - Hôpitaux de Paris Phase 3 2007-06-01 Besides liver transplantation, the curative treatment of primary hepatic cancer with cirrhosis remains the surgical resection. Radiofrequency or cryotherapy currently allow local ablation of small cancer, with very good results. However, all these treatments are followed by high rates of recurrence (50 - 70% at 5 years). Then, it seems essential to associate to the surgical resection or to the local ablation as "adjuvant" treatment, in order to prevent or to decrease the rate of recurrence. However, no evidence supports this attitude. Therefore, following curative treatment of primary hepatic cancer with cirrhosis, we propose to compare treated to untreated patients. Postoperative treatment means either intra-arterial chemotherapy or systemic chemotherapy. The main criterion of the study is time of survival without recurrence. The main secondary objective is the safety.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LIPIODOL

Condition Name

Condition Name for LIPIODOL
Intervention Trials
Hepatocellular Carcinoma 19
Carcinoma, Hepatocellular 7
Liver Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LIPIODOL
Intervention Trials
Carcinoma, Hepatocellular 35
Carcinoma 29
Liver Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LIPIODOL

Trials by Country

Trials by Country for LIPIODOL
Location Trials
China 17
United States 15
France 10
India 3
Taiwan 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LIPIODOL
Location Trials
Pennsylvania 4
California 3
Maryland 2
Washington 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LIPIODOL

Clinical Trial Phase

Clinical Trial Phase for LIPIODOL
Clinical Trial Phase Trials
Phase 4 9
Phase 3 12
Phase 2/Phase 3 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LIPIODOL
Clinical Trial Phase Trials
Recruiting 12
Unknown status 12
Not yet recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LIPIODOL

Sponsor Name

Sponsor Name for LIPIODOL
Sponsor Trials
Shanghai Zhongshan Hospital 6
Guerbet 6
Sun Yat-sen University 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LIPIODOL
Sponsor Trials
Other 159
Industry 10
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.